Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Exenatide

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

AstraZeneca · Phase 3 · Terminated · Enrollment 13

NCT03419624

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
Dapagliflozin plus Exenatiden/rn/rn/rn/rn/r
Placebo plus Placebon/rn/rn/rn/rn/r
Placebo plus Exenatiden/rn/rn/rn/rn/r

A count stays a count. This page does not turn a count into a percent.